A phase 1b human trial evaluated the safety of the GM‐CSF‐expressing herpes‐based oncolytic virus tamimogene laherparepvec (weeks 1, 4, 6, every 2 weeks) combined with systemic pembrolizumab (week 6, every 2 weeks) for treatment of MM. This evidence concerns the gene CSF2 and Miyoshi myopathy.